Approved Study Database
| Ref. No. | Scientific Title | Principal investigator |
|---|---|---|
| 2018.334 | A MULTICENTER, OPEN-LABEL, LONG-TERM EXTENSION OF PHASE III STUDIES (BN29552/BN29553) OF CRENEZUMAB IN PATIENTS WITH ALZHEIMER’S DISEASE |
Prof. MOK Vincent Chung Tong 莫仲棠 |
| 2011.238 | Comparative assessment of difference in reward processing of the brain among normal subjects, stroke patients and major depressive disorder patients | Prof. MOK Vincent Chung Tong |
| 2008.240 | A Pilot Study Using Pittsburg Compound-B Positron Emission Tomography in the Evalulation of Poststroke Dementia | Prof Mok Vincent Chung Tong |
| 2010.540 | Transcranial Doppler Ultrasound for Detection of Cerebral White Matter Changes in High-Risk Population | Prof Mok Vincent Chung Tong |
| 2011.090 | Risk index for screening subclinical brian lesions in communitydwelling elderly persons in Hong Kong | Prof. MOK Vincent Chung Tong |
| 2009.495 | Early Identificaion of significant subclinical brain lesions in community-dwelling elderly persons in Hong Kong | Prof Mok Vincent Chung Tong |
| 2014.023 | Hong Kong Registry of Early Onset Dementia | Prof. MOK Vincent Chung Tong |
| 2011.406 | Adaptation of the Booklet Category Test in Chinese: A pilot study | Prof MOK Vincent Chung Tong |
| 2013.433 | Development of normative data for NINDS - Canadian Stroke Network Vascular Cognitive Impairment Neuropsychology Protocols | Prof. MOK Vincent Chung Tong |
| 2009.032 | Neuroimaging Predictors for Cognitive Impairment in Chinese Patients with Confluent White Matter Lesion | Prof Mok Vincent Chung Tong |
| 2009.530 | Efficacy of Rivastigmine Transdermal Patch in Dementia Patients who do not benefit from Oral Acetylcholinesterase Inhibitors (AChIs) | Prof Mok Vincent Chung Tong |
| 2013.025 | Cilostazol and Cerebral Haemodynamics in Cerebral Small Vessel Disease | Prof. Mok Vincent Chung Tong |
| 2022.374 | Quantitative Neuroimaging Index for Early Detection of Dementia |
Prof. MOK Vincent Chung Tong 莫仲棠 |
| 2024.548 | The BRaIn diseases, Fundus PhotoGrapHy and OCT (BRIGHT) Registry | Prof. MOK Vincent Chung Tong |
| 2024.607 | A Patient Registry for Early Detection and Management of Alzheimer’s Disease in Hong Kong | Prof. MOK Vincent Chung Tong |
| 2024.549 | Validation of the MRI-based Alzheimer’s Disease Resemblance Atrophy Index and Plasma-Based Biomarkers on Alzheimer’s Disease | Prof. MOK Vincent Chung Tong |
| 2016.065 | Identifying Fluctuators in Parkinson's Disease with Objective Assessment Technology |
Prof. MOK Vincent C.T. 莫仲棠 |
| 2015.574 | Establishment of reference genome of Hong Kong population for biomarker identification in Alzheimer's disease |
Prof. MOK Vincent C.T. 莫仲棠 |
| 2015.449 | mPower - Mobile Parkinson’s Disease Study |
Dr. MOK Vincent C.T. 莫仲棠 |
| 2012.167 | MicroRNA expression pattern in stroke patients: a pilot study | Prof Mok Vincent C.T |
| 2013.681 | A nested case-control study to investigate microRNA as a screening biomarker for asymptomatic elders with white matter hyperintensities at risk of incident dementia and stroke | Prof. Mok Vincent C T |
| 2008.023 | Mechanisms for Cognitive Impairment in Chinese Patients with Confluent White Matter Lesion: Analysis of 99 Structural Brain Regions Using a Hybrid Volumetric and Surface Warping | Prof Mok Vincent |
| 2014.276 | Danshen and Gegen in improving Cerebral Haemodynamics in Cerebral White Matter Hyperintensities: A Pilot Study | Prof. MOK Vincent |
| 2013.660 | Evaluation of the need of CM services for stroke patients in Hong Kong | Prof. MOK Vincent |
| 2019.371 | Biomarkers in Neurodegenerative Diseases (NDD Registry) |
Prof. MOK Vincent 莫仲棠 |
| 2020.536 | Enhancing Use of Telemedicine among Older People amid COVID-19 In Asia (EUTOPIA ) | Prof. MOK Vincent |
| 2014.213 | Physiological basis of motor facilitation by visual cues in Parkinson's disease | Prof Mok Vincent |
| 2023.348 | Brain Heath Service for Prevention of AD |
Prof. MOK Vincent 莫仲棠 |
| 2008.249 | Randomized, Open Label, Phase III Trial of CP-751, 871 in Combination with Paclitaxel and Carboplatin versus Paclitaxel and Carboplatin in Patients with Non-Small Cell Lung Cancer | Prof MOK Tony, S.K. |
| 2007.246 | A Double-Blind, Randomized, Placebo-Controlled Phase III Study to Assess the Efficacy of recMAGE-A3 + AS15 Antigen Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients with Resectable MAGE-A3-Positive Non-Small Cell Lung Cancer | Prof. MOK Tony SK |
| 2013.461 | A multicenter, open-label, randomized phase II study to evaluate the efficacy of AUY922 vs pemetrexed or docetaxel in NSCLC patients with EGFR mutations who have progressed on prior EGFR TKI treatment | Prof. MOK Tony Shu Kam |
| 2009.393 | INSPIRE - Stimuvax trial In Asian NSCLC Patients: stimulating Immune REsponse A multi-national, double-blind, placebo-controlled, randomized, phase III clinical trial of the cancer vaccine Stimuvax® (L-BLP25 or BLP25 liposome vaccine) in Asian subjects with stage III, unresectable, non-small cell lung cancer (NSCLC) who have demonstrated either stable disease or objective response following primary chemo-radiotherapy | Prof. MOK Tony Shu Kam |
| 2011.179 | A Randomized Phase 3 Study Comparing First-Line Pemetrexed plus Cisplatin (Followed by Gefitinib as Maintenance) with Gefitinib Monotherapy in East Asian (Never Smoker or Light Ex-Smoker) Patients with Locally Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer | Prof. Mok Tony Shu Kam |
| 2010.390 | Randomized controlled trial of S-1 versus docetaxel in patients with non-small cell lung cancer who have received a platinum-based treatment | Prof. MOK Tony Shu Kam |
| 2011.028 | An open-label multi-center study of erlotinib (Tarceva®) as first line therapy until and beyond RECIST progression in NSCLC patients who harbor EGFR mutations | Prof. MOK Tony Shu Kam |
| 2009.594 | A Phase 2, Multicenter, Randomized Study of Two Different Dose Regimens of Eribulin Mesylate in Combination with Intermittent Erlotinib in Patients with Previously Treated, Advanced Non-Small Cell Lung Cancer | Prof. MOK Tony Shu Kam |
| 2012.218 | LUX-Lung 7: A randomised, open label Phase IIb Trial of afatinib versus gefitinib as first-line treatment of patients with EGFR mutation positive advanced adenocarcinoma of the lung | Prof. MOK Tony Shu Kam |
| 2012.422 | A phase II, multicenter, single-arm study of oral LDK378 in adult patients with ALK-activated non-small cell lung cancer previously treated with chemotherapy and crizotinib | Prof. MOK Tony Shu Kam |
| 2012.430 | A Global Phase 3, Randomized, Placebo-Controlled, Double-Blind Trial of AMG 706 in Combination With Paclitaxel and Carboplatin for Advanced Non-Squamous Non-Small Cell Lung Cancer (Asian Phase 3 Study) | Prof. MOK Tony Shu Kam |
| 2012.473 | PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF THE EFFICACY AND SAFETY OF CRIZOTINIB VERSUS PEMETREXED/CISPLATIN OR PEMETREXED/CARBOPLATIN IN PREVIOUSLY UNTREATED EAST ASIAN PATIENTS WITH NON-SQUAMOUS CARCINOMA OF THE LUNG HARBORING A TRANSLOCATION OR INVERSION EVENT INVOLVING THE ANAPLASTIC LYMPHOMA KINASE (ALK) GENE LOCUS | Prof. MOK Tony Shu Kam |
| 2013.167 | A Multicenter, Open-Label Phase 2 Study of the Safety and Activity of Lenvatinib (E7080) in Subjects With KIF5B-RET-Positive Adenocarcinoma of the Lung | Prof. MOK Tony Shu Kam |
| 2013.089 | ARCHER 1050: A RANDOMIZED, OPEN-LABEL, PHASE 3, EFFICACY AND SAFETY STUDY OF DACOMITINIB (PF-00299804) VERSUS GEFITINIB FOR THE FIRST LINE TREATMENT OF LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER IN SUBJECTS WITH EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) ACTIVATING MUTATION(S) | Prof. MOK Tony Shu Kam |
| 2021.631 | A Randomized Phase 3 Study of MRTX849 versus Docetaxel in Patients with Previously Treated Non-Small Cell Lung Cancer with KRAS G12C Mutation |
Prof. MOK Tony Shu Kam 莫樹錦 |
| 2022.075 | An Open-label, Multicenter, Phase 2 Study of Sacituzumab Govitecan Combinations in First-line Treatment of Patients with Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) Without Actionable Genomic Alterations |
Prof. MOK Tony Shu Kam 莫樹錦 |
| 2024.593 | A Phase Ib/II Dose Finding Study Assessing Safety and Efficacy of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Extensive Stage Small Cell Lung Cancer (ES-SCLC) in Combination with Carboplatin, Etoposide and Atezolizumab in Induction and with Atezolizumab in Maintenance Phase | Prof. MOK Tony Shu Kam |
| 2016.086 | Phase II Study of AZD9291 in patients with advanced stage non-small cell lung cancer following prior EGFR TKI Therapy with EGFR and T790M mutations detected in plasma circulating tumor DNA |
Prof. MOK Tony Shu Kam 莫樹錦 |
| 2013.572 | A PHASE II, MULTICENTER, SINGLE-ARM STUDY OF ATEZOLIZUMAB IN PATIENTS WITH PD-L1-POSITIVE LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER | Prof. MOK Tony Shu Kam |
| 2015.582 | A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 in Combination with Tremelimumab Therapy Versus Standard of Care Platinum-Based Chemotherapy in First Line Treatment of Patients with Advanced or Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE) |
Prof. MOK Tony Shu Kam 莫樹錦教授 |
| 2016.597 | Open-Label, Randomized Trial of Nivolumab (BMS-936558) plus Pemetrexed/Platinum or Nivolumab plus Ipilimumab (BMS-734016) vs Pemetrexed plus Platinum in Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC) Subjects with Epidermal Growth Factor Receptor (EGFR) Mutation Who Failed 1L or 2L EGFR Tyrosine Kinase Inhibitor Therapy |
Prof. MOK Tony Shu Kam 莫樹錦教授 |
| 2017.423 | A Phase III, Randomized, Multi-Center, Open-Label, Comparative Global Study to Determine the Efficacy of Durvalumab or Durvalumab and Tremelimumab in Combination With Platinum-Based Chemotherapy for First-Line Treatment in Patients With Metastatic Non-Small-Cell Lung Cancer (NSCLC) (POSEIDON) |
Prof. MOK Tony Shu Kam 莫樹錦 |
Page 91 of 262.